NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Losses hit ATEC shareholders in late October 2026 when Alphatec Holdings (NASDAQ: ATEC) cut its full-year 2026 revenue outlook to approximately $862 million, naming a temporary international supply constraint among the causes, and the stock sold off sharply in after-hours trading. If ATEC cost you money, now is the time to have those losses reviewed. Investors who suffered losses are encouraged to get their ATEC losses evaluated now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
On the Company's August 4, 2026 second-quarter earnings call, Chief Executive Officer Patrick Miles told investors: "International growth has proved our clinical distinction model translates globally." The transcript of that call does not reference a pending or potential upcoming international supply constraint. Fewer than three months later, that constraint appeared in the Company's explanation for the reduced outlook.
Levi & Korsinsky is investigating potential violations of the federal securities laws. The investigation focuses on whether Alphatec may not have adequately disclosed the international supply constraint to investors before the Company cited it in the revised 2026 revenue outlook.
Shareholders who lost money on ATEC can submit their loss details for review today or call Joseph E. Levi, Esq. at (212) 363-7500.
WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
Frequently Asked Questions About the ATEC Investigation
Q: Who is eligible to participate in the ATEC investigation? A: Investors who purchased ATEC stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Alphatec Holdings made materially false or misleading statements regarding its full-year 2026 outlook, including the approximately $882 million guidance maintained on August 4, 2026. When the Company disclosed a reduced outlook of approximately $862 million alongside third-quarter 2026 results that fell shy of analyst consensus, the stock price declined sharply.
Q: What do ATEC investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my ATEC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ATEC and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. If you choose to participate in any resulting action, these matters are generally handled on a contingency basis, and any attorneys' fees and expenses are subject to court approval.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
